From WikiPathways
ArcPathVisio Brace Ellipse EndoplasmicReticulum GolgiApparatus HexagonPathVisio MimDegradation Mitochondria Octagon PentagonPathVisio Rectangle RoundedRectangle SarcoplasmicReticulum TriangleEquilateralEast TrianglePathVisio none JAK / STAT pathway PI3K / Akt pathway RAS / MAPK pathway Tyrosine kinase inhibitors (TKI) MEK Cell growth Survival Migration / invasion Angiogenesis JAK1 JAK2 JAK3 TYK2 Cetuximab Panitumumab Erlotinib Gefitinib Lapatinib Dacomitinib Afatinib Neratinib PDK1 STAT3 AKT1 AKT2 AKT3 TSC1 TSC2 RHEB MTOR RPTOR EGFR EREG BTC TGFA EGF KRAS HRAS NRAS SOS1 SOS2 GRB2 PTEN RAF1 MAP2K1 MAP2K2 MAP2K3 MAP2K4 MAP2K5 MAP2K6 MAP2K7 RAS STAT3 STAT3 STAT3 STAT3 STAT3 EGFR EGFR PIP3 PIP2 JAK1 JAK2 JAK3 TYK2 RHEB 1st generation 2nd generation mTORC1 JAK JAK KRAS HRAS NRAS Anti-EGFR mAbs Dimerization Inactive EGFR (monomer) Active EGFR (dimer) Glioblastoma cell Nucleus Name: Tyrosine kinase inhibitors in glioblastoma Organism: Homo sapiens
Description
Draft new pathway diagram
Try the New WikiPathways
View approved pathways at the new wikipathways.org .
Quality Tags
Review changes for Approved Revision 135824 of this pathway was approved for data analysis by Egon Willighagen .
Ontology Terms
Saving...
Bibliography
Manzanares-Guzmán A, Lugo-Fabres PH, Camacho-Villegas TA; ''vNARs as Neutralizing Intracellular Therapeutic Agents: Glioblastoma as a Target.''; Antibodies, 2024 PubMed Europe PMC Scholia
History
External references
DataNodes
Annotated Interactions
No annotated interactions